Week In Review: InvoX, A Sino Biopharma Company, To Pay $161 Million To Acquire F-Star

InvoX Pharma, a Sino Biopharma subsidiary, will pay $161 million to acquire F-Star, a clinical stage company developing bispecific drugs for immunotherapies. Meanwhile, Reistone Biopharma completed a Series A financing of nearly $100 million.